{"title":"校正有效利用 RWD 进行外部控制：关于监管和 HTA 决策的系统文献综述》。","authors":"","doi":"10.1002/cpt.3453","DOIUrl":null,"url":null,"abstract":"<p>Sola-Morales, O. <i>et al</i>. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. <i>Clin. Pharmacol. Ther</i>. <b>114</b>, 325–355 (2023). https://doi.org/10.1002/cpt.2914</p><p>The following adjustments should be made to the text:\n </p><p>\n <b>References</b>\n </p><p>124. NICE. Asfotase alfa for treating paediatric-onset hypophosphatasia <https://www.nice.org.uk/guidance/hst6> (2017). Accessed 24 May, 2024.</p><p>125. NICE. Onasemnogene abeparvovec for treating spinal muscular atrophy https://www.nice.org.uk/guidance/hst15 (2021). Accessed 24 May, 2024.</p><p>126. GBA. Certinib. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3496/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_TrG.pdf> (2015). Accessed 24 May, 2024.</p><p>127. GBA. Efmoroctocog alfa. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3824/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195_TrG.pdf> (2016). Accessed 24 May, 2024.</p><p>128. GBA. Nivolumab. Supporting Grounds <https://www.g-ba.de/downloads/40-268-4426/2017-06-15_AM-RL-XII_Nivolumab_D-267_TrG.pdf> (2017). Accessed 12 August, 2024.</p><p>129. NICE. Vismodegib for treating basal cell carcinoma <https://www.nice.org.uk/guidance/ta489> (2017). Accessed 24 May, 2024.</p><p>We hope that these updates improve the interpretation and clarity of this manuscript.</p>","PeriodicalId":153,"journal":{"name":"Clinical Pharmacology & Therapeutics","volume":"117 1","pages":"289-308"},"PeriodicalIF":6.3000,"publicationDate":"2024-11-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.3453","citationCount":"0","resultStr":"{\"title\":\"Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions\",\"authors\":\"\",\"doi\":\"10.1002/cpt.3453\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Sola-Morales, O. <i>et al</i>. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. <i>Clin. Pharmacol. Ther</i>. <b>114</b>, 325–355 (2023). https://doi.org/10.1002/cpt.2914</p><p>The following adjustments should be made to the text:\\n </p><p>\\n <b>References</b>\\n </p><p>124. NICE. Asfotase alfa for treating paediatric-onset hypophosphatasia <https://www.nice.org.uk/guidance/hst6> (2017). Accessed 24 May, 2024.</p><p>125. NICE. Onasemnogene abeparvovec for treating spinal muscular atrophy https://www.nice.org.uk/guidance/hst15 (2021). Accessed 24 May, 2024.</p><p>126. GBA. Certinib. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3496/2015-12-17_AM-RL-XII_Ceritinib_2015-07-01-D-171_TrG.pdf> (2015). Accessed 24 May, 2024.</p><p>127. GBA. Efmoroctocog alfa. Supporting Grounds <https://www.g-ba.de/downloads/40-268-3824/2016-06-16_AM-RL-XII_Efmoroctocog-alfa_D-195_TrG.pdf> (2016). Accessed 24 May, 2024.</p><p>128. GBA. Nivolumab. Supporting Grounds <https://www.g-ba.de/downloads/40-268-4426/2017-06-15_AM-RL-XII_Nivolumab_D-267_TrG.pdf> (2017). Accessed 12 August, 2024.</p><p>129. NICE. Vismodegib for treating basal cell carcinoma <https://www.nice.org.uk/guidance/ta489> (2017). Accessed 24 May, 2024.</p><p>We hope that these updates improve the interpretation and clarity of this manuscript.</p>\",\"PeriodicalId\":153,\"journal\":{\"name\":\"Clinical Pharmacology & Therapeutics\",\"volume\":\"117 1\",\"pages\":\"289-308\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2024-11-15\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cpt.3453\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Clinical Pharmacology & Therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://onlinelibrary.wiley.com/doi/10.1002/cpt.3453\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"PHARMACOLOGY & PHARMACY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Pharmacology & Therapeutics","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpt.3453","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
Correction to Effectively Leveraging RWD for External Controls: A Systematic Literature Review of Regulatory and HTA Decisions
Sola-Morales, O. et al. Effectively leveraging RWD for external controls: a systematic literature review of regulatory and HTA decisions. Clin. Pharmacol. Ther. 114, 325–355 (2023). https://doi.org/10.1002/cpt.2914
The following adjustments should be made to the text:
References
124. NICE. Asfotase alfa for treating paediatric-onset hypophosphatasia <https://www.nice.org.uk/guidance/hst6> (2017). Accessed 24 May, 2024.
125. NICE. Onasemnogene abeparvovec for treating spinal muscular atrophy https://www.nice.org.uk/guidance/hst15 (2021). Accessed 24 May, 2024.
期刊介绍：
Clinical Pharmacology & Therapeutics (CPT) is the authoritative cross-disciplinary journal in experimental and clinical medicine devoted to publishing advances in the nature, action, efficacy, and evaluation of therapeutics. CPT welcomes original Articles in the emerging areas of translational, predictive and personalized medicine; new therapeutic modalities including gene and cell therapies; pharmacogenomics, proteomics and metabolomics; bioinformation and applied systems biology complementing areas of pharmacokinetics and pharmacodynamics, human investigation and clinical trials, pharmacovigilence, pharmacoepidemiology, pharmacometrics, and population pharmacology.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
